Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

European urology - 1 Jun 2016

Cheng Heather H, Pritchard Colin C, Boyd Thomas, Nelson Peter S, Montgomery Bruce

Abstract excerpt

Understanding the molecular underpinnings of sensitivity to specific therapies will advance the goal of precision medicine in prostate cancer (PCa). We identified three patients with metastatic castration-resistant PCa (mCRPC) who achieved an exceptional response to platinum chemotherapy (not first-line treatment for PCa), despite disease progression on prior standard therapies. Using targeted next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA2
Share to Carboplatin
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Doxorubicin

Share to Prostatectomy

Share to Prostatic Neoplasms, Castration-Resistant

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 26724258
DOI: 10.1016/j.eururo.2015.11.022
PMCID: PMC4909531

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.PMID 26724258Read ↗

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Semantic proximity Read ↗

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Semantic proximity Read ↗

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.Semantic proximity Read ↗

Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.Semantic proximity Read ↗

Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experienceSemantic proximity Read ↗

DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentSemantic proximity Read ↗

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.Semantic proximity Read ↗

Molecular landscape of prostate cancer: Implications for current clinical trialsSemantic proximity Read ↗

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the ClinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.